About Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals is a Healthcare company based in Princeton (United States) founded in 2015, and was acquired by Viatris in November 2022. Gene therapies for ophthalmological diseases are developed. Oyster Point Pharmaceuticals has raised $121.61 million across 2 funding rounds from investors including Viatris, Invus and Flying L Partners. The company has 303 employees. Its chief executive, as recorded, is Jeffrey Nau. Oyster Point Pharmaceuticals offers products and services including EFFEXOR and Generics. Its focus areas include Life Sciences, Ophthalmology, Drugs and Dry-Eye Diseases. Its legal entity is OYSTER POINT PHARMA, INC. Its competitors include TearSolutions, Retrotope and Lineage Cell Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2015 and headquartered in Princeton, United States, the company focuses on biotechnology within the ophthalmology sector. Gene therapies targeting ocular surface diseases are developed using an adeno-associated virus-based approach known as Enriched Tear Film therapy. The pipeline encompasses OC-01, a nasal spray for dry-eye disease; OC-103, intended for severe allergic conjunctivitis; and OC-101, aimed at neurotrophic keratopathy. Operations center on advancing these therapies through clinical development.
- Headquarters Princeton, United States
- Employees 303
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website oysterpointrx.com
- Social LinkedIn X
- Acquired by Viatris (Nov 2022)
- Legal Name Oyster Point Pharma, Inc.
Products & Services of Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals offers a comprehensive portfolio of products and services, including EFFEXOR and Generics.
Medication for treating generalized anxiety disorder.
Affordable alternatives to branded drugs for various conditions.
Funding Insights of Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals has successfully raised a total of $121.61M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $93 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $121.61M
- Total Rounds 2
- Last Round Series B — $93M
- First Round $28.61M
(Oct 2017)
- Investors Count 5
All 2 funding rounds of Oyster Point Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $93M | Series B | – | Invus, Flying L Partners | |
| Oct 2017 | $28.61M | Series A | – | New Enterprise Associates, Versant Ventures | – |
6 investors in total: 6 institutional.
Investors in Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Viatris, Invus and Flying L Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Flying L Partners is focused on ophthalmic sector investments. | flyinglpartners.com | |||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Branded pharmaceuticals are developed and commercialized by Viatris internationally. | 1998 | viatris.com | Frankfurt, Germany |
Investor details for Oyster Point Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Oyster Point Pharmaceuticals
37 people are tracked at Oyster Point Pharmaceuticals (11 in leadership, 4 in board & advisors, 22 in team); the tracked headcount is 303.
| Name | Role | Group |
|---|---|---|
Jeffrey Nau | CEO | Leadership |
Daniel Lochner | CFO | Leadership |
Marian Macsai | Chief Medical Officer, Medical Affairs | Leadership |
Karen Castillo-Paff | VP, Communications & Public Relations | Leadership |
Yovanka Djokic Rn | Associate Director Pharmacovigilance And Risk | Leadership |
Jack Markey | Executive Director Of Accounting | Leadership |
Dessa Chittester | Senior Director Of Operations, Chief Scientific Office | Leadership |
Bill O'Brien | Director, Supply Chain & Logistics | Leadership |
John Lazarczyk | Associate Director Of Finance | Leadership |
Erin Cummings | Director, Human Resources Business Partner | Leadership |
Pam Hartman | Senior Director, Patient Services | Leadership |
Ali Behbahani | Director | Board & advisors |
Mark Murray | Director | Board & advisors |
Benjamin Tsai | Director | Board & advisors |
Clare Ozawa | Director | Board & advisors |
Amy Takacs | Territory Manager | Team |
Traci Whitmer | Territory Manager | Team |
Gina Barnes | Territory Manager | Team |
Brooke Tomlinson | Eye Care Territory Manager | Team |
Mandy Honeycutt | Eye Care Territory Manager | Team |
17 more people are available in the full profile.
Complete people profiles for Oyster Point Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Oyster Point Pharmaceuticals
5 dated milestones of Oyster Point Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Oyster Point Pharmaceuticals is founded.
- Funding First funding round of $28.6M.
- Funding Latest funding round, Series B, of $93.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Viatris.
Competitors of Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include TearSolutions, Retrotope and Lineage Cell Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tearsolutions.com | 2013 | Charlottesville, United States | $43.56M | Topical therapeutics for the treatment of dry eye disease | ||
| retrotope.com | 2006 | Los Altos, United States | $58.58M | Therapeutics for neurodegenerative and ophthalmological diseases are developed. | ||
| lineagecell.com | 1990 | Carlsbad, United States | $45.8M | 75 | Lineage Cell Therapeutics is focused on developing allogeneic cell therapies. |
Detailed competitors of Oyster Point Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Oyster Point Pharmaceuticals (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oyster Point Pharmaceuticals
Complete news archive for Oyster Point Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Oyster Point Pharmaceuticals is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Jeffrey Nau is the CEO of Oyster Point Pharmaceuticals, as recorded in our data.
Oyster Point Pharmaceuticals is a funded company, having raised a total of $121.61M across 2 funding rounds to date. The company's 1st funding round was a Series A of $28.61M, raised on Oct 2017.
Oyster Point Pharmaceuticals has 303 employees.
Annual revenue of Oyster Point Pharmaceuticals is $24.54M as on Dec 31, 2021.
Founded in 2015 and headquartered in Princeton, United States, the company focuses on biotechnology within the ophthalmology sector. Gene therapies targeting ocular surface diseases are developed using an adeno-associated virus-based approach known as Enriched Tear Film therapy. The pipeline encompasses OC-01, a nasal spray for dry-eye disease; OC-103, intended for severe allergic conjunctivitis; and OC-101, aimed at neurotrophic keratopathy. Operations center on advancing these therapies through clinical development.
Oyster Point Pharmaceuticals's top competitors include Lineage Cell Therapeutics, TearSolutions and Retrotope.
Oyster Point Pharmaceuticals offers EFFEXOR and Generics.
Oyster Point Pharmaceuticals has 6 investors. Key investors include Viatris, Invus, Flying L Partners, NEA, and Versant Ventures.
Oyster Point Pharmaceuticals operates through Oyster Point Pharma, Inc..
Yes. Oyster Point Pharmaceuticals was acquired by Viatris in November 2022.